10-12 September 2018 //  Lancaster Royal Hotel, London


Welcome to the 3rd Annual Phacilitate Cell & Gene Therapy Europe.  

Meet the future of ATMP commercialisation at Europe’s premier partnering event for advancing cell and gene therapy business models

The only European event that offers extensive specific coverage of ATMP R&D, manufacturing and regulatory issues and challenges, whilst also placing these components in their wider strategic context at the core of successful cell & gene therapy business and commercialization models.  

No other cell and gene therapy on the continent draws as many vital stakeholders, including:

  • The EU's leading regulators, HTAs and payers, each providing critical, need-to-know insight for anyone seeking to develop and commercialise ATMPs.  
  • Pharma decision makers actively seeking partnering opportunities in this space. 
  • Investors looking to back European ATMP companies today


Join 300 ATMP industry decision-makers and key external stakeholder leaders at the event which defines the strategic roadmap to success for the world’s cell & gene therapy developers and manufacturers, ensuring European patients gain access to the game-changing biotherapeutics of tomorrow.

Meet the key senior European executives, as well as the global cell and gene therapy community, with job titles at the 2016 event including:


Head of Global Medical Affairs & EU Clinical Development

VP & Head of Gene Therapy Development

SVP, Clinical & Regulatory

VP, Manufacturing

VP, Cell & Gene Therapy Product Development & Supply

Senior Director, Scientific Affairs & Analysis

Global Head of Clinical Development

Chief Executive Officer

Chief Medical Officer

Chief Regulatory & Compliance Officer




2017 Speakers

"It was a very interesting event as all participants, including speakers were ready to exchange, even on the most challenging subjects such as reimbursement, GMP guidance."

Bertrand Alexandre, Director, Marketing Europe, Celyad